Swipe om te navigeren naar een ander artikel
Despite benefits of antiretroviral therapies (ART), people with HIV infection have increased risk of cardiovascular disease, kidney disease, and low bone mineral density. Some ARTs increase risk of these events. The purpose of this study was to examine patients’ perspectives of these risks and estimate health state utilities associated with these risks for use in cost-utility models.
Qualitative thematic analysis was conducted to examine messages posted to the POZ/AIDSmeds Internet community forums, focusing on bone, kidney, and cardiovascular side effects and risks of HIV/AIDS medications. Then, health state vignettes were drafted based on this qualitative analysis, literature review, and clinician interviews. The health states (representing HIV, plus treatment-related risks) were valued in time trade-off interviews with general population participants in the UK.
Qualitative analysis of the Internet forums documented patient concerns about ART risks, as well as treatment decisions made because of these risks. A total of 208 participants completed utility interviews (51.4% female; mean age 44.6 years). The mean utility of the HIV health state (virologically suppressed, treated with ART) was 0.86. Adding a description of risk resulted in statistically significant disutility (i.e., utility decreases): renal risk (disutility = −0.02), bone risk (−0.03), and myocardial infarction risk (−0.05).
Patient concerns and treatment decisions were documented via qualitative analysis of Internet forum discussions, and the impact of these concerns was quantified in terms of health state utilities. The resulting disutilities may be useful for differentiating among ARTs in economic modeling of treatment for patients with HIV.
UNAIDS. (2015). How AIDS changed everything—MDG6: 15 years, 15 lessons of hope from the AIDS response; 380; http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf. Accessed 17 Aug 2015.
World Health Organization (WHO). (Updated July 2015). HIV/AIDS Fact Sheet 2015. http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed 17 Aug 2015.
Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine, 338(13), 853–860. CrossRefPubMed
Durand, M., Sheehy, O., Baril, J. G., Lelorier, J., & Tremblay, C. L. (2011). Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. Journal of Acquired Immune Deficiency Syndromes, 57(3), 245–253. CrossRefPubMed
Lang, S., Mary-Krause, M., Cotte, L., Gilquin, J., Partisani, M., Simon, A., et al. (2010). Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Archives of Internal Medicine, 170(14), 1228–1238. CrossRefPubMed
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El-Sadr, W., Dabis, F., et al. (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. The Journal of Infectious Diseases, 201(3), 318–330. CrossRefPubMed
McComsey, G. A., Kitch, D., Daar, E. S., Tierney, C., Jahed, N. C., Tebas, P., et al. (2011). Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. The Journal of Infectious Diseases, 203(12), 1791–1801. CrossRefPubMedPubMedCentral
Sax, P.E., Gallant, J.E., and Klotman, P.E. (2007). Renal safety of tenofovir disoproxil fumarate. AIDS Read, 17(2), 90–2, 99–104, C3.
Foglia, E., Bonfanti, P., Rizzardini, G., Bonizzoni, E., Restelli, U., Ricci, E., et al. (2013). Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. PLoS ONE, 8(2), e57777. CrossRefPubMedPubMedCentral
Maggiolo, F., Colombo, G. L., Di Matteo, S., Bruno, G. M., Astuti, N., Di Filippo, E., et al. (2015). Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Related Outcome Measures, 6, 53–60. PubMedPubMedCentral
Brazier, J. R., Ratcliffe, J., Salomon, J. A., & Tsuchiya, A. (2007). Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press.
Feeny, D. (2005). Preference-based measures: utility and quality-adjusted life years. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (pp. 405–431). New York: Oxford University Press.
Lara, A. M., Wakholi, B. N., Kasirye, A., Munderi, P., Watera, C., Lalloo, D. G., et al. (2008). Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. AIDS, 22(Suppl 1), 123–130. CrossRef
Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Medical Care, 33(4 Suppl), AS173–A82. PubMed
Humphrey, L., Mahapatra, R., Trundell, D., Kitchen, H. (2015, 7–11 November 2015). Patient-reported outcomes & patient preference research issues: blog it, tweet it, like it, or bin it? The Role of Social Media Data in Patient-reported Outcomes Research (IP5). Issue Panel: Sesion I at ISPOR 18th Annual European Congress. Milan, Italy.
NICE (National Institute for Health and Care Excellence) (2013). Process and methods guides: Guide to the methods of technology appraisal 2013. London: NICE.
Auerbach, C. F., & Silverstein, L. B. (2003). Qualitative data: an introduction to coding and analysis. New York: NYU Press.
Boyatzis, R. E. (1998). Transforming qualitative information: thematic analysis and code development. Thousand Oaks, CA: Sage Publications.
Gibson, W. J., & Brown, A. (2009). Working with qualitative data. London: Sage Publications. CrossRef
CADTH (Canadian Agency for Drugs and Technologies in Health). (2006). Guidelines for the economic evaluation of health technologies: Canada, Ottawa: CADTH.
PBAC (Pharmaceutical Benefits Advisory Committee). (2013). Guidelines for preparing submissions to PBAC, Version 4.4. Canberra: Australian Government Department of Health, PBAC.
Rowen, D., & Brazier, J. (2011). Health Utility Measurement. In S. Glied & P. Smith (Eds.), The oxford handbook of health economics (pp. 788–813). New York: Oxford University Press.
Davies, E. W., Matza, L. S., Worth, G., Feeny, D. H., Kostelec, J., Soroka, S., et al. (2015). Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes, 13, 90. CrossRefPubMedPubMedCentral
Lewis, E. F., Li, Y., Pfeffer, M. A., Solomon, S. D., Weinfurt, K. P., Velazquez, E. J., et al. (2014). Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT stud (valsartan in acute myocardial infarction). JACC Heart Fail, 2(2), 159–165. CrossRefPubMed
Preece, J., Nonnecke, B., & Andrews, D. (2004). The top five reasons for lurking: improving community experiences for everyone. Computers in Human Behavior, 20(2), 201–223. CrossRef
DAD Study Group, et al. (2007). Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine, 356(17), 1723–1735. CrossRef
DAD Study Group, et al. (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 371(9622), 1417–1426. CrossRef
Palella, F. J. Jr., Althoff, K. N., Moore, R., Zhang, J., Kitahata, M., Gange, S. J., et al. (2015, February 23–26). Abacavir use and risk for myocardial infarction in the NA-ACCORD. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA.
Sabin, C. A., Reiss, P., Ryom, L., De Wit, S., Kirk, O., Weber, R., et al. (2014, March 3–6). Is there continued evidence for an association between abacavir and myocardial infarction risk? Poster presented at 21st Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA
Ribaudo, H. J., Benson, C. A., Zheng, Y., Koletar, S. L., Collier, A. C., Lok, J. J., et al. (2011). No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clinical Infectious Diseases, 52(7), 929–940. CrossRefPubMedPubMedCentral
Fux, C. A., Simcock, M., Wolbers, M., Bucher, H. C., Hirschel, B., Opravil, M., et al. (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral Therapy, 12(8), 1165–1173. PubMed
Nishijima, T., Kawasaki, Y., Tanaka, N., Mizushima, D., Aoki, T., Watanabe, K., et al. (2014). Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS, 28(13).
- Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation
Louis S. Matza
Karen C. Chung
Katherine J. Kim
Trena M. Paulus
Evan W. Davies
Katie D. Stewart
Grace A. McComsey
Marshall W. Fordyce
- Springer International Publishing